Literature DB >> 21321143

Synergism between outer membrane proteins and antimicrobials.

P Veiga-Crespo1, E Fusté, T Vinuesa, M Viñas, T G Villa.   

Abstract

Antibiotic-resistant bacteria are becoming one of the most important problems in health care because of the number of resistant strains and the paucity of new effective antimicrobials. Since antibiotic-resistant bacteria will continue to increase, it is necessary to look for new alternative strategies to fight against them. It is generally accepted that Gram-negative bacteria are intrinsically less susceptible than Gram-positive bacteria to antimicrobials. The main reason is that Gram-negative bacteria are surrounded by a permeability barrier known as the outer membrane (OM). Hydrophilic solutes most often cross the OM through water-filled channels formed by a particular family of proteins known as porins. This work explores the possibility of using exogenous porins to lower the required amounts of antibiotics (ampicillin, ciprofloxacin, cefotaxime, clindamycin, erythromycin, and tetracycline). Porins had a bactericidal effect on Escherichia coli cultures, mainly in the logarithmic phase of growth, when combined with low antibiotic concentrations. The use of different antibiotic-porin mixtures showed a bactericidal effect greater than those of antibiotics and porins when used separately. It was possible to observe different behaviors according to the antibiotic type used.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21321143      PMCID: PMC3088225          DOI: 10.1128/AAC.01786-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  TolC, a macromolecular periplasmic 'chunnel'.

Authors:  K Postle; H Vakharia
Journal:  Nat Struct Biol       Date:  2000-07

Review 2.  Molecular basis of bacterial outer membrane permeability revisited.

Authors:  Hiroshi Nikaido
Journal:  Microbiol Mol Biol Rev       Date:  2003-12       Impact factor: 11.056

Review 3.  TolC--the bacterial exit duct for proteins and drugs.

Authors:  Vassilis Koronakis
Journal:  FEBS Lett       Date:  2003-11-27       Impact factor: 4.124

Review 4.  Structure and function of TolC: the bacterial exit duct for proteins and drugs.

Authors:  Vassilis Koronakis; Jeyanthy Eswaran; Colin Hughes
Journal:  Annu Rev Biochem       Date:  2004       Impact factor: 23.643

5.  AcrA, AcrB, and TolC of Escherichia coli Form a Stable Intermembrane Multidrug Efflux Complex.

Authors:  Elena B Tikhonova; Helen I Zgurskaya
Journal:  J Biol Chem       Date:  2004-05-20       Impact factor: 5.157

Review 6.  Multidrug efflux pumps of gram-negative bacteria.

Authors:  H Nikaido
Journal:  J Bacteriol       Date:  1996-10       Impact factor: 3.490

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  AcrAB Efflux System: Expression and Contribution to Fluoroquinolone Resistance in Klebsiella spp.

Authors:  Annarita Mazzariol; Jessica Zuliani; Giuseppe Cornaglia; Gian Maria Rossolini; Roberta Fontana
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

9.  Detection and prevalence of active drug efflux mechanism in various multidrug-resistant Klebsiella pneumoniae strains from Turkey.

Authors:  Ufuk Over Hasdemir; Jacqueline Chevalier; Patrice Nordmann; Jean-Marie Pagès
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  Role of TolC in Klebsiella oxytoca resistance to antibiotics.

Authors:  Anna Fenosa; Ester Fusté; Lidia Ruiz; Patricia Veiga-Crespo; Teresa Vinuesa; Victor Guallar; Tomas G Villa; Miguel Viñas
Journal:  J Antimicrob Chemother       Date:  2009-02-24       Impact factor: 5.790

View more
  1 in total

1.  Vitamin D Pretreatment Attenuates Ciprofloxacin-Induced Antibacterial Activity.

Authors:  Majed M Masadeh; Karem H Alzoubi; Bashar M Al-Taani; Majd M Masadeh; Zainah O Aburashed; Nasr Alrabadi
Journal:  Clin Pharmacol       Date:  2020-10-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.